Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

May 21, 2014

Integrated Phenotypic Screening and Target Deconvolution for Accelerated Drug Discovery

Speakers for this Event:
  • Mark Slack, PhD, Vice President, In Vitro Pharmacology, Evotec
  • Stefan Müller, PhD, Head of Chemical Biology, Evotec
  • Using phenotypic screens as a strategy to identify potential drug candidates has gained renewed attention in recent years. The aim is to identify chemical matter that corrects disease-relevant cellular phenotypes with the potential to be truly disease-modifying. To this end, Evotec has established innovative and novel disease-relevant screening paradigms. This webinar will provide insight into Evotec’s approach to phenotypic screening for hit ID in the context of complex & novel biological systems.

    Understanding the mechanism and binding partner(s) of any hit compounds identified from phenotypic screening has posed a challenge for many years. Evotec’s Cellular Target Profiling™ approach combines quantitative mass spectrometry based chemical proteomics to identify the target(s) of small molecule hit compounds. The technology uses cells to reveal a compound’s cellular binding partners including binding affinities thus allowing deciphering the network of intracellular targets and enabling lead optimization.

    The webinar will focus on:

    • Use of novel disease-relevant cellular systems for hit ID including the use of stem cells
    • Characterization and prioritization of hits for target identification post HTS
    • Target deconvolution through mass spec-based Cellular Target Profiling


    Application areas: Cell Biology, High Content Screening, Phenotypic Screening, Target Identification, Target Validation

    Therapeutic areas: Cancer, Oncology, Metabolic, Inflammation, CNS, Cardiovascular, Rare Diseases


    Mark Slack, PhD, Vice President, In Vitro Pharmacology, Evotec

    Mark Slack is VP in vitro Pharmacology where he is responsible for providing scientific and leadership function within both client and Evotec´s drug discovery programs. Mark Joined Evotec in 2002 after two years at Bayer Healthcare and prior to that a Post-doc at the Max-Planck institute for Neurological Research in Cologne, Germany. Mark is directly responsible for managing the in vitro activities within Evotec associated with the oncology and CNS units, working with chemistry and in vivo groups both internal and external to bring compounds through the value chain. In addition, the in vitro pharmacology group is responsible for all HCS activities and stem cell activities where Mark was influential in establishing and expanding these to the world leading platform it is today.

    Stefan Müller, PhD, Head of Chemical Biology, Evotec

    Stefan Müller received his PhD from the University of Würzburg working on the specificity of heterotrimeric G-proteins. He spent 2 ½ years as a postdoc at Caltech in Pasadena, CA, studying mice with gene disruption of G-proteins. From 1999 to 2001 he worked as a scientist at Boehringer Ingelheim performing transcription profiling with cellular material from COPD patients. In 2001 he joined Axxima Pharmaceuticals as a group leader for genomics investigating the role of kinases in the host defense of infectious diseases. After acquisition of Axxima by GPC Biotech his focus shifted to kinase targets and their role in cancer. In 2008 he joined Kinaxo Biotechnologies as Head of Chemical Biology being responsible for chemical proteomics projects and the development of novel approaches to study the mode-of-action of epigenetic drugs. In 2011 Kinaxo became Evotec (München) GmbH.


    Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.

    Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease.

    Evotec is built on integrated drug discovery know-how of more than 15 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional major operations are based in Abingdon, UK, Göttingen, Munich, Germany, San Francisco and Branford, USA. Evotec has more than 600 employees worldwide.

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Share this:

    Copyright © 2016-2017 Honeycomb Worldwide Inc.